))
AI is Not Sci-Fi: The Potential of Artificial Intelligence in Drug Discovery
Manage episode 353582105 series 3310882
Innhold levert av Danish Diabetes and Endocrine Academy, Danish Diabetes, and Endocrine Academy. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Danish Diabetes and Endocrine Academy, Danish Diabetes, and Endocrine Academy eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
AI is dramatically changing the landscape of drug discovery in research today, but what is needed for the best outcomes? How do we overcome the challenges?
Artificial intelligence is not the future anymore; it is happening now – and it is happening on a grand scale.
Academic researchers and pharmaceutical companies have started utilising AI to aid in drug discovery. Drug discovery is a lengthy and costly process, with average research and development for new drugs taking 10-20 years and costing billions of dollars. New approaches are needed, and looking to AI might unlock potential that we have not yet imagined. But are there costs?
Listen as an expert in AI and machine learning and an experimental biologist discuss the evolution, applications of AI and its possible uses in medical research.
Guests:
Per Greisen, Director of Computational Drug Discovery at Novo Nordisk.
Hande Topel, Postdoctoral researcher in a functional genomics and metabolism unit at the University of Southern Denmark
Host:
Gretchen Repasky, Communications Director, Nordic EMBL Partnership for Molecular Medicine and the University of Helsinki.
Publisher:
Danish Diabetes and Endocrine Academy
Producer:
Kontekst & Lyd
You can find additional information about the podcast at www.ddeacademy.dk/podcasts
19 episoder
Del
